Skip to main content
PMC home page
Gut logoLink to Gut
. 1980 Jul;21(7):632–635. doi: 10.1136/gut.21.7.632

Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.

P A van Hees, J H Bakker, J H van Tongeren
PMCID: PMC1419886  PMID: 6107263

Abstract

Suppositories of sulphapyridine, 5-aminosalicylic acid, and placebo were used in 45 patients with idiopathic proctitis to determine the active part of sulphasalazine. Each patient used one of the suppositories twice daily for four weeks in a double-blind controlled trial. Complete clinical remission with normal rectal mucosa on sigmoidoscopy occurred in 60% of patients given 5-aminosalicylic acid, but in only 13% and 27% of those given sulphapyridine and placebo respectively. Twelve patients were included twice. In eight of these patients 5-aminosalicylic acid was given one time and sulphapyridine (two patients) or placebo (six patients) another time. Clinical remission occurred in each patient with 5-aminosalicylic acid, but in only one patient during other therapy. The results suggest that 5-aminosalicylic acid is the active therapeutic moiety of sulphasalazine.

Full text

PDF
632

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azad Khan A. K., Piris J., Truelove S. C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977 Oct 29;2(8044):892–895. doi: 10.1016/s0140-6736(77)90831-5. [DOI] [PubMed] [Google Scholar]
  2. BARON J. H., CONNELL A. M., LENNARD-JONES J. E., JONES F. A. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet. 1962 May 26;1(7239):1094–1096. doi: 10.1016/s0140-6736(62)92080-9. [DOI] [PubMed] [Google Scholar]
  3. BARON J. H., CONNELL A. M., LENNARD-JONES J. E. VARIATION BETWEEN OBSERVERS IN DESCRIBING MUCOSAL APPEARANCES IN PROCTOCOLITIS. Br Med J. 1964 Jan 11;1(5375):89–92. doi: 10.1136/bmj.1.5375.89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. DICK A. P., GRAYSON M. J., CARPENTER R. G., PETRIE A. CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS. Gut. 1964 Oct;5:437–442. doi: 10.1136/gut.5.5.437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Farmer R. G., Brown C. H. Ulcerative proctitis: course and prognosis. Gastroenterology. 1966 Aug;51(2):219–223. [PubMed] [Google Scholar]
  6. Folley J. H. Current concepts: ulcerative proctitis. N Engl J Med. 1970 Jun 11;282(24):1362–1364. doi: 10.1056/NEJM197006112822407. [DOI] [PubMed] [Google Scholar]
  7. Hansson K. A., Sandberg M. Determination of sulphapyridine and its metabolites in biological materials after administration of salicylazosulphapyridine. Acta Pharm Suec. 1973 Mar;10(1):87–92. [PubMed] [Google Scholar]
  8. LENNARD-JONES J. E., COOPER G. W., NEWELL A. C., WILSON C. W., JONES F. A. Observations on idiopathic proctitis. Gut. 1962 Sep;3:201–206. doi: 10.1136/gut.3.3.201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Peppercorn M. A., Goldman P. Distribution studies of salicylazosulfapyridine and its metabolites. Gastroenterology. 1973 Feb;64(2):240–245. [PubMed] [Google Scholar]
  10. Pieniaszek H. J., Jr, BatesTR Colorimetric determination of 5-aminosalicylic acid and its N-acetylated metabolite on urine and feces. Res Commun Chem Pathol Pharmacol. 1975 Nov;12(3):571–581. [PubMed] [Google Scholar]
  11. Schröder H., Campbell D. E. Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther. 1972 Jul-Aug;13(4):539–551. doi: 10.1002/cpt1972134539. [DOI] [PubMed] [Google Scholar]
  12. Sparberg M., Fennessy J., Kirsner J. B. Ulcerative proctitis and mild ulcerative colitis: A study of 220 patients. Medicine (Baltimore) 1966 Sep;45(5):391–412. doi: 10.1097/00005792-196609000-00003. [DOI] [PubMed] [Google Scholar]
  13. TRUELOVE S. C. Suppository treatment of haemorrhagic proctitis. Br Med J. 1959 Apr 11;1(5127):955–958. doi: 10.1136/bmj.1.5127.955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. van Hees P. A., Tuinte J. H., van Rossum J. M., van Tongeren J. H. Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin). Gut. 1979 Apr;20(4):300–304. doi: 10.1136/gut.20.4.300. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES